Kenta Biotech AG
  • Home
  • Shop
  • Events
  • Courses
  • Services
  • Pricing
  • Company
    • News
    • Success Stories
    • About Us
  • Appointment
  • Contact us
  • 0
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
Kenta Biotech AG
  • 0
    • Home
    • Shop
    • Events
    • Courses
    • Services
    • Pricing
    • Company
      • News
      • Success Stories
      • About Us
    • Appointment
    • Contact us
  • +1 (718) 513-2983
  • Sign in
  • Contact Us
  1. Products
  2. Rabbit Polyclonals
Public Pricelist
Public Pricelist
Sort By: Featured
Featured Newest Arrivals Name (A-Z) Price - Low to High Price - High to Low

Rabbit Polyclonals

[0118-70R-9499] Human, Mouse Lyrm4 Rabbit polyclonal antibody - 100 ul
Human, Mouse Lyrm4 Rabbit polyclonal antibody - 100 ul
810.00 € 810.0 EUR
[0855-ELK6825-96T] Human PABPC1L(Poly A Binding Protein Cytoplasmic 1 Like Protein) ELISA Test - 96 Tests
Human PABPC1L(Poly A Binding Protein Cytoplasmic 1 Like Protein) ELISA Test - 96 Tests
444.00 € 444.0 EUR
[0622-AF1979] Human Otx2 Affinity Purified Polyclonal Ab
Human Otx2 Affinity Purified Polyclonal Ab
690.00 € 690.0 EUR
[0088-32232-05111] Human MD-1 polyclonal antibody - 150 ug.
Human MD-1 polyclonal antibody - 150 ug.
458.00 € 458.0 EUR
[0399-CSB-PA840992LC01HU-50ug.] Human C1orf54 Polyclonal Antibody, FITC-conjug.ated - 50 ug.
Human C1orf54 Polyclonal Antibody, FITC-conjug.ated - 50 ug.
275.00 € 275.0 EUR
[0356-A58348-050] Human C1orf54 Polyclonal Antibody, FITC-conjug.ated - 50 ug.
Human C1orf54 Polyclonal Antibody, FITC-conjug.ated - 50 ug.
452.00 € 452.0 EUR
[0399-CSB-PA840992LC01HU-100ug.] Human C1orf54 Polyclonal Antibody, FITC-conjug.ated - 100ug.
Human C1orf54 Polyclonal Antibody, FITC-conjug.ated - 100ug.
374.00 € 374.0 EUR
[0356-A58348-100] Human C1orf54 Polyclonal Antibody, FITC-conjug.ated - 100 ug.
Human C1orf54 Polyclonal Antibody, FITC-conjug.ated - 100 ug.
579.00 € 579.0 EUR
[0399-CSB-PA840992LD01HU-100ug.] Human C1orf54 Polyclonal Antibody Biotin-conjug.ated - 100ug.
Human C1orf54 Polyclonal Antibody Biotin-conjug.ated - 100ug.
374.00 € 374.0 EUR
[0399-CSB-PA840992LA01HU-50ug.] Human C1orf54 Polyclonal Antibody - 50 ug.
Human C1orf54 Polyclonal Antibody - 50 ug.
275.00 € 275.0 EUR
[0399-CSB-PA840992LA01HU-100ug.] Human C1orf54 Polyclonal Antibody - 100 ug.
Human C1orf54 Polyclonal Antibody - 100 ug.
374.00 € 374.0 EUR
[0708-HPAB-1558-FY-S(P)-500ug.] Human Anti-IL18 E. coli Rec. Antibody (clone H1L2); scFv Fragment-Regular Endotoxin Batch, SDS-PAGE>95%, His-tag, 0.5 mG.
Human Anti-IL18 E. coli Rec. Antibody (clone H1L2); scFv Fragment-Regular Endotoxin Batch, SDS-PAGE>95%, His-tag, 0.5 mG.
4,890.00 € 4890.0 EUR
[0708-HPAB-1558-FY-500ug.] Human Anti-IL18 E. coli Rec. Antibody (clone H1L2) -Regular Endotoxin Batch, SDS-PAGE>95%, 0.5 mG.
Human Anti-IL18 E. coli Rec. Antibody (clone H1L2) -Regular Endotoxin Batch, SDS-PAGE>95%, 0.5 mG.
4,450.00 € 4450.0 EUR
[0708-HPAB-0649-CN] Human Anti-IL18 E. coli Rec. Antibody (HPAB-0649-CN)  -Regular batch (without endotoxin removal), SDS-PAGE>95%
Human Anti-IL18 E. coli Rec. Antibody (HPAB-0649-CN) -Regular batch (without endotoxin removal), SDS-PAGE>95%
3,640.00 € 3640.0 EUR
[0708-PABJ-0221-FITC-2mG.] Human Anti-IAV H2N2 NA E. coli Rec. Antibody (clone 1G01) Conjug.ation: FITC Purity: SDS-PAGE>95% Endotoxin: Non-removal 2mG.
Human Anti-IAV H2N2 NA E. coli Rec. Antibody (clone 1G01) Conjug.ation: FITC Purity: SDS-PAGE>95% Endotoxin: Non-removal 2mG.
12,240.00 € 12240.0 EUR
[0708-PABJ-0221-FITC-1mG.] Human Anti-IAV H2N2 NA E. coli Rec. Antibody (clone 1G01) -Regular batch (without endotoxin removal), SDS-PAGE > 95%, FITC 1mG.
Human Anti-IAV H2N2 NA E. coli Rec. Antibody (clone 1G01) -Regular batch (without endotoxin removal), SDS-PAGE > 95%, FITC 1mG.
6,980.00 € 6980.0 EUR
[0708-PABJ-0147] Human Anti-HIV-1 Env E. coli Rec. Antibody (clone ACS202) - SDS-PAGE>95%, Regular batch (without endotoxin removal), 0.5 mG.
Human Anti-HIV-1 Env E. coli Rec. Antibody (clone ACS202) - SDS-PAGE>95%, Regular batch (without endotoxin removal), 0.5 mG.
4,049.00 € 4049.0 EUR
[0708-PABX-031-1mG.] E. coli Rec. Mouse Anti-CD28 Antibody 1mG.
E. coli Rec. Mouse Anti-CD28 Antibody 1mG.
6,143.00 € 6143.0 EUR
[0708-PABL-212-PE-1mG.] E. coli Rec. Human monoclonal Anti-IAV HA Antibody, CR9114, -Regular batch, without endotoxin removal, SDS-PAGE >95%, PE 1mG.
E. coli Rec. Human monoclonal Anti-IAV HA Antibody, CR9114, -Regular batch, without endotoxin removal, SDS-PAGE >95%, PE 1mG.
6,980.00 € 6980.0 EUR
[0708-PABL-212-PE-2mG.] E. coli Rec. Human monoclonal Anti-IAV HA Antibody, CR9114 Conjug.ation: PE Purity: SDS-PAGE>95% Endotoxin: Non-removal 2mG.
E. coli Rec. Human monoclonal Anti-IAV HA Antibody, CR9114 Conjug.ation: PE Purity: SDS-PAGE>95% Endotoxin: Non-removal 2mG.
12,240.00 € 12240.0 EUR
  • 5
  • 6
  • 7
  • 8
  • 9

Clear Filters



Respiratory syncytial virus (RSV) infections are the most common cause of hospitalization in early childhood, accounting for 57 000 to 120 000 hospitalizations each year in the United States. RSV is causing annual epidemics of bronchiolitis and pneumonia worldwide. In most cases the infection with RSV heals without sequelae, yet RSV infection can cause lung function deterioration and in some circumstances, years of recurrent wheezing or asthma may ensue. Overall RSV accounts for an estimated2% of the hospitalization rate among infants less than 1 year of age. This rate increases 4–5-fold among high-risk patients such as premature infants and those with chronic lung disease or complicated congenital heart disease.


Currently there is only one possibility to prevent infections of at-risk patients with RSV, namely immuno-prophylaxis with palivizumab/Synagis, marketed by MedImmune. However, the response to palivizumab is variable among individuals, and sometimes palivizumab fails to prevent RSV infections effectively.


Due to the lack of better antibodies, lack of effective anti-viral treatment and lack of an effective preventive vaccine for RSV, there is a substantial medical need for more efficacious prophylactic immunizations, e.g. by antibody.


Kenta Biotech had developed a fully human monoclonal antibody (KBRV201) derived from B-cells of a human donor. KBRV201 is of the human IgG1 isotype with specificity and very high affinity for the F-protein of human respiratory syncytial virus (hRSV). KBRV201 has been tested for recognition and neutralization of hRSV strains -A, -B and –Long, and KBRV201 could neutralize in vitro all strains tested with higher efficacy than other anti-F-protein mAb.




KBRV201 successfully recognizes 22 clinical isolates from children infected with RSV, including one isolate with a mutated F-protein. Overall KBRV201 has demonstrated superiority in every experiment performed, and KBRV201 is currently undergoing extensive testing in animal models.

14009 NW Harbor Ln, Portland, OR 97229, USA.


Follow us
Copyright © 2025 Kenta Biotech AG
English (UK) English (US)